Compare Moody's Corporation (MCO) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moody's Corporation vs Summit Therapeutics Inc — how do they compare? Moody's Corporation trades at $464.23 (market cap $79.44B), while Summit Therapeutics Inc trades at $17.59 (market cap $13.71B). The key difference: Moody's Corporation is far larger — about 5.8× Summit Therapeutics Inc's market cap, and Moody's Corporation pays a 0.9% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Moody's Corporation for 132 Days and Summit Therapeutics Inc for 16 Days on average.
| MCO | SMMT | |
|---|---|---|
Market Cap | $79.44B | $13.71B |
Volume | 526,684 | 6,173,057 |
Sector | Financials | Health |
52-Week High | $539.61 | $26.38 |
52-Week Low | $412.23 | $12.43 |
Typical Hold Time | 132 Days | 16 Days |
Enterprise Value | $85.46B | $13.04B |
Dividend Yield | 0.9% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MCO trades at $458.69, up 2.01% today, with a bearish technical signal but strong fundamentals. Revenue grew to $7.72B in 2025, with net income margin expanding to 34.25%. Recent news highlights Moody's top RiskTech100 ranking and expansion into Asia-Pacific via a PhilRatings stake. The stock faces resistance near $461, with support at $454.
Outlook remains positive given consistent earnings beats, high profitability, and a $536.40 analyst price target implying 17% upside. Risks include high valuation multiples and macroeconomic sensitivity. Institutional sentiment is bullish with 56% buy ratings, though technical indicators suggest near-term caution.
Summit Therapeutics (SMMT) trades at $17.17, down 4.35% on the day, amid mixed technical signals with a bullish moving average trend but neutral oscillators. The company reported no revenue in 2025 and a net loss of $1.08 billion, with negative ROE and ROA, yet maintains a high P/B ratio of 21.76. Recent positive sentiment is driven by a $2 billion strategic investment from AstraZeneca and expanded clinical collaborations for its lead drug ivonescimab, as reported by Reuters and Business Wire on September 28-29, 2026.
The outlook hinges on clinical success; upside exists if ivonescimab trials meet endpoints, supported by strong analyst consensus (65% buy rating) and a $29.33 price target. Key risks include cash burn from negative operating cash flow, drug development failures, and reliance on partnership outcomes, posing significant volatility for investors despite institutional interest.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moody's Corporation
Moody's, along with S&P Ratings, is a leading provider of credit ratings on fixed income securities. Moody's ratings segment, known as Moody's Investors Service or MIS, includes corporates, structured finance, financial institutions, and public finance ratings. MIS represents a majority of the firm's revenue and profits. Moody's other segment is Moody's Analytics and consists of Research, Data, and Analytics or RD&A and Enterprise Risk Solutions or ERS. RD&A's products include credit research, quantitative credit scores, economic research, business intelligence, know your customer (KYC) tools, commercial real estate data and analytical tools, and training services. ERS includes risk management software solutions to financial institutions.
Read more on MCO →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
